This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Cawood, C. Search for Related Content Social Bookmarking                   What's this?

Methemoglobinemia Secondary to Primaquine Therapy in an HIV Patient with Pneumocystis carinii Pneumonia—A Case Report

Purpose: To describe an adverse drug event in a human immunodeficiency virus (HIV) patient treated with primaquine for Pneumocystis carinii (PCP) pneumonia. Summary: A 29-year-old black male presented to the outpatient clinic with symptoms of shortness of breath, nausea, and stomach cramps. The patient had received 10 days of primaquine 15 mg po q d and clindamycin 450 mg po qid for active PCP infection. The patient was found to have a methemoglobin level of 3%. The patient was diagnosed with primaquine-induced methemoglobinemia and admitted to the hospital. He was treated with methylene blue 120 mg IV, prednisone 40 mg po bid (tapered), ascorbic acid 500 mg po q d, and pentamidine 200 mg IV q 24 hrs. During the hospital course, the patient stabilized and was discharged upon completion of his pentamidine therapy. Conclusions: Reporting adverse drug events with all HIV-related therapies is key to enhancing the awareness and possibly preventing future adverse events.

Journal of Pharmacy Practice, Vol. 10, No. 3, 132-133 (1997)
DOI: 10.1177/089719009701000304


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?